Compare Natera Inc. Common Stock (NTRA) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SAP SE — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while SAP SE trades at $221.95 (market cap $254.61B). The key difference: SAP SE is far larger — about 4.5× Natera Inc. Common Stock's market cap, and SAP SE pays a 1.33% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SAP SE for 118 Days on average.
| NTRA | SAP | |
|---|---|---|
Market Cap | $57.03B | $254.61B |
Volume | 1,131,157 | 1,684,839 |
Sector | Health | Technology |
52-Week High | $425.64 | $280.46 |
52-Week Low | $179.42 | $146.38 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $56.18B | $253.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SAP trades at $219.75, up 0.87% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $36.8B in 2025 and a net income margin of 20.41%. Recent earnings show a mix of beats and one miss, while analyst consensus is a Buy with a $253.60 price target. Cloud revenue growth of 24% in Q2 2026 and AI initiatives are key drivers, though competition and margin pressures from cloud transitions pose challenges.
The outlook for SAP is positive, supported by robust cloud adoption and AI integration, offering potential upside to the consensus target. Risks include execution on AI capabilities, competitive threats from new entrants, and macroeconomic sensitivity in software spending. The stock's valuation at a P/E of 29.48 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
